Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POEM plus nifedipine to prevent esophageal cancer in esophageal motility disorders
jRCTs031250002Recruiting
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of nifedipine in achalasia, esophagogastric junction outflow obstruction (EGJOO), Diffuse Esophageal Spasm (DES) and 1 more. Primary endpoint: Change in p53 positivity in esophageal biopsy specimens. Started May 2025; status: recruiting.
02
Drugs
nifedipine
03
Conditions
achalasiaesophagogastric junction outflow obstruction (EGJOO)Diffuse Esophageal Spasm (DES)Hypercontractile Esophagus (HE)
Beyond the preview
Go deeper on jRCTs031250002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250002.